SURISimplify Propel Opportunities ETF

Diversifier3y track recordRanked #194 of 240 in this goal

Seeks long-term capital appreciation.

By Simplify Asset Management · Launched 2023

Annual Cost

2.56%

#5,527 of 5,562 · expensive

Fund Size

$75M

#3,185 of 5,562 · mid-size

Return (1Y)Goal

+26.5%

Track Record

3 years

#2,928 of 5,562 · seasoned

Performance

Total-return NAV · USD

Growth of $10,000

$12,697+27.0%

Total-return NAV, USD. Net of fund fees, before tax.

Classification

How Beacon categorizes this fund

Asset class

Fixed income

Region

North america

Strategy

Multi strategy

What it actually holds

By weight

Concentration

Top 10 holdings = 115.9% of fundconcentrated

TREASURY BILL

39.4%

Plains GP Holdings LP

32.4%

DREYFUS TRSY OBLIG CASH M

10.8%

Achieve Life Sciences Inc

7.8%

Phathom Pharmaceuticals Inc

7.1%

Viridian Therapeutics Inc

4.3%

Milestone Pharmaceuticals Inc

4.0%

Delcath Systems Inc

3.5%

Abeona Therapeutics Inc

3.5%

Celldex Therapeutics Inc

3.1%

Asset allocation

Stocks

98.3%

Bonds

1.1%

Cash

0.5%

Risk profile

Last 12 months · Sharpe & Sortino need 3+ years

Volatility (1Y)

22.4%High

Year-on-year price swings

Max drawdown

-47.8%Severe

Worst peak-to-trough loss

Sharpe (3Y)

0.22Below average

Sortino (3Y)

0.30Moderate downside risk

Bond profile

Duration

5.6 years

Credit ratings

AAA

19.1%

29.3%

27.8%

BBB

23.7%

Other

0.1%

Where to buy

Listing

Exchange: NYSE Arca

Full fund details

Objective: Seeks long-term capital appreciation.
Strategy: Actively managed ETF concentrating investments in biotechnology, pharmaceuticals, healthcare technology, and life sciences. Utilizes a multi-asset strategy including stocks, bonds, and derivatives to enhance returns.
Inception date: February 7, 2023
Fund family: Simplify Asset Management